| NCT ID | NCT05623956 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aalborg University Hospital |
| Condition | Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-03-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: * Written and signed informed consent * Histopathologically and/or cytologically newly-diagnosed SCLC * Measurable disease on CT scans * Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide Exclusion Criteria: * Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * Treatment with any other investigational agent
Contact & Investigator
Weronika Szejniuk, MD, PhD
PRINCIPAL INVESTIGATOR
Aalborg University Hospital
Frequently Asked Questions
Who can join the NCT05623956 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05623956 currently recruiting?
Yes, NCT05623956 is actively recruiting participants. Contact the research team at anbd@rn.dk for enrollment information.
Where is the NCT05623956 trial being conducted?
This trial is being conducted at Aalborg, Denmark.
Who is sponsoring the NCT05623956 clinical trial?
NCT05623956 is sponsored by Aalborg University Hospital. The principal investigator is Weronika Szejniuk, MD, PhD at Aalborg University Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.